000			03456nam a22003975i 4500
001			88196
003			ES-MaUEC
005			20230207040627.0
007			cr nn 008mamaa
008			161128s2016 gw | s |||| 0|eng d
020			_a9783319465050
024	7		_a10.1007/978-3-319-46505-0 _2doi
040			_aES-MaUEC
050		4	_aRC280.B7 _bR475 2016 EB
245	0	0	_aResistance to targeted therapies against adult brain cancers _cedited by Amanda Tivnan
260			_aCham _bSpringer International Publishing _c2016
300			_a1 recurso en línea (XVI, 260 p.) _b19 ilustraciones, 16 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	1		_aResistance to Targeted Anti-Cancer Therapeutics _x2196-5501
505	0		_aTargeted therapies in gliomas: An overview -- Targeting chemotherapy resistance in glioblastoma through modulation of ABC transporters -- Resistance of Glioblastomas to Radiation Therapy -- The blood-brain barrier in glioblastoma multiforme: Pathology and therapeutic implications -- Resistance of brain tumours to small-molecule targeted therapies: lessons from various cancer types -- Drug repurposing to circumvent chemotherapy resistance in brain tumours -- Small molecule inhibitors in glioblastoma: Key pathways and resistance mechanisms -- Imaging Targeted Therapy Response and Resistance in Glioblastoma -- Drug Resistance in Malignant Meningiomas -- Recurrence of Low-Grade Glioma - Have the Targeted Therapies Improved for Better Outcomes? -- Host-Tumor Interactions in Brain Cancer Metastasis Leading to Drug Resistance
520			_aThis volume will bring together a review of research being carried out by international experts in this field, detailing treatment and research approaches in several forms of malignant brain tumors. These include glioblastoma (GBM), a highly aggressive and fatal form of astrocytoma which accounts for 80% of newly diagnosed brain tumor patients per year, and meningioma, of which 10% are malignant and extremely resistant to targeted therapies. The volume will also include a discussion of methods to overcome blood-brain barrier exclusion for more efficient targeted drug delivery in all forms of brain cancer treatment. The volume will include information on the repurposing of drugs in an attempt to circumvent drug resistance, use of small molecule inhibitors in GBM treatment, mechanisms of secondary brain metastasis, drug resistance, and state-of-the-art imaging of targeted therapies
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGER
650		7	_aCerebro _xTumores _9214753 _2embne
650		7	_aCáncer _xInvestigación _2embne _9182523
650		7	_aCiencias biomédicas _2embne _9143729
700	1		_aTivnan, Amanda _eeditor literario _9101727 _0Local
830		0	_aResistance to Targeted Anti-Cancer Therapeutics _x2196-5501 _0http://id.loc.gov/authorities/names/n2013186812 _9133185
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-46505-0zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319465050
907			_a.b12982003 _b10-10-17 _c08-03-17
998			_am _a_alco _a_vill _b30-06-17 _cm _dz _eb _feng _ggw _h0
945			_aRC280 .B7 R475 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11603847 _z06-04-17
999			_c88196 _d88196 _x1